TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
about
Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells
P2860
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
TAK-228 (formerly MLN0128), an ...... h advanced solid malignancies.
@ast
TAK-228 (formerly MLN0128), an ...... h advanced solid malignancies.
@en
type
label
TAK-228 (formerly MLN0128), an ...... h advanced solid malignancies.
@ast
TAK-228 (formerly MLN0128), an ...... h advanced solid malignancies.
@en
prefLabel
TAK-228 (formerly MLN0128), an ...... h advanced solid malignancies.
@ast
TAK-228 (formerly MLN0128), an ...... h advanced solid malignancies.
@en
P2093
P2860
P1476
TAK-228 (formerly MLN0128), an ...... h advanced solid malignancies.
@en
P2093
C D Kurkjian
Howard A Burris
J R Infante
P B Murphy
R Neuwirth
P2860
P2888
P356
10.1007/S00280-017-3343-4
P577
2017-06-10T00:00:00Z
P6179
1085967971